With a median follow-up time of 88.1 months, the AML patients with higher HOXB-AS3 expressions had shorter OS and RFS than those with lower HOXB-AS3 expressions (Fig. 4a and b; median OS, 17.7 months versus not reached, P value < 0.0001; median RFS, 12.9 months versus not reached, P value 0.0070, respectively). This evidence concerns the gene PDS5B and acute myeloid leukemia.